Stem Cell News

BioInformant's coverage of stem cell news includes iPS cells, mesenchymal stem cells, hematopoietic stem cells, neural stem cells and more.

As the first and only market research firm to specialize in stem cell news, BioInformant research has been cited by the Wall Street Journal, Xconomy, AABB, and Vogue Magazine.

Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry news.

Longeveron LLC Announces Completion of Enrollment in Phase 1 Clinical Trial of Longeveron Allogeneic Mesenchymal Stem Cells (LMSCs) in Alzheimer’s Disease

February 18, 2020 By Cade Hildreth, Founder & President Leave a Comment

MIAMI, Dec. 20, 2019 — Longeveron LLC, a leading developer of adult stem cell technologies for chronic, aging-related and life-threatening conditions, announced today that it has completed enrollment in its Phase 1 Alzheimer’s disease trial. This randomized, double-blind, placebo-controlled study is designed to evaluate the safety and efficacy of LMSCs in patients with mild Alzheimer’s disease (AD). [Read more…]

First Dosing in Plexoval Exosome Wound Healing Human Study

January 31, 2020 By Cade Hildreth, Founder & President Leave a Comment

Highlights

First human dosing of Plexaris™ has occurred in Exopharm’s PLEXOVAL Study
PLEXOVAL is a world-first study using a cell free, platelet-derived exosome product manufactured using Exopharm’s proprietary LEAP Technology for wound healing
Other pre-clinical development progress will be reported over coming months

MELBOURNE, Australia – Jan. 29, 2020 11:00 UTC — Regenerative medicine company Exopharm Limited (ASX:EX1) announces first dosing has occurred in the PLEXOVAL Phase I study using exosomes isolated from human platelets for wound healing, Exopharm’s first human clinical trial. Further participants are expected to soon follow in this study that involves up to 20 participants. [Read more…]

INTELLiSTEM Announces the Launch of a New Antigen Identification Platform for the Development of Novel CAR T Cells

January 13, 2020 By Cade Hildreth, Founder & President Leave a Comment

TORONTO, ON, JANUARY 13, 2020 –– INTELLiSTEM Technologies, an international biotechnology company revolutionizing cell therapy, announces today the launch of IntelliPeptidome^TM, a novel Drug Discovery Platform for rapid and systematic identification of MHC/HLA bound peptide candidates for various clinical applications. [Read more…]

Aegle Therapeutics Raises $4M to Fund First Trial in the U.S. Using Exosomes from Allogeneic MSCs

January 11, 2020 By Cade Hildreth, Founder & President Leave a Comment

Aegle Therapeutics raises $4 million to fund a groundbreaking stem cell exosome clinical trial to treat the orphan disease, Dystrophic Epidermolysis Bullosa.

BOSTON and MIAMI, Jan. 7, 2020 — Aegle Therapeutics Corp., a first in class biotechnology company isolating extracellular vesicles, including exosomes (“EVs”), secreted by mesenchymal stem cells as therapy, announced the closing of a $4M financing. Aegle’s platform technology is initially being developed to treat dystrophic epidermolysis bullosa (“DEB”), a rare pediatric skin blistering disorder. [Read more…]

Charles River Laboratories Completes Acquisition of HemaCare for $380 Million Cash

January 10, 2020 By Cade Hildreth, Founder & President Leave a Comment

Charles River Laboratories (NYSE: CRL) has completed its acquisition of HemaCare Corporation (OTCMKTS: HEMA) for $380 million in cash, or $25.40 per HemaCare share. [Read more…]